- Home
- EDUC vs AYTU Comparison
EDUC vs AYTU Comparison
Compare EDUC & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDUC
- AYTU
- Stock Information
- Founded
- EDUC 1965
- AYTU N/A
- Country
- EDUC United States
- AYTU United States
- Employees
- EDUC N/A
- AYTU N/A
- Industry
- EDUC Consumer Specialties
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- EDUC Consumer Discretionary
- AYTU Health Care
- Exchange
- EDUC Nasdaq
- AYTU Nasdaq
- Market Cap
- EDUC 10.1M
- AYTU 8.3M
- IPO Year
- EDUC N/A
- AYTU N/A
- Fundamental
- Price
- EDUC $1.20
- AYTU $1.05
- Analyst Decision
- EDUC
- AYTU
- Analyst Count
- EDUC 0
- AYTU 0
- Target Price
- EDUC N/A
- AYTU N/A
- AVG Volume (30 Days)
- EDUC 6.9K
- AYTU 31.3K
- Earning Date
- EDUC 05-21-2025
- AYTU 05-14-2025
- Dividend Yield
- EDUC N/A
- AYTU N/A
- EPS Growth
- EDUC N/A
- AYTU N/A
- EPS
- EDUC N/A
- AYTU N/A
- Revenue
- EDUC $36,523,200.00
- AYTU $77,232,000.00
- Revenue This Year
- EDUC N/A
- AYTU N/A
- Revenue Next Year
- EDUC N/A
- AYTU $8.14
- P/E Ratio
- EDUC N/A
- AYTU N/A
- Revenue Growth
- EDUC N/A
- AYTU N/A
- 52 Week Low
- EDUC $0.92
- AYTU $0.95
- 52 Week High
- EDUC $2.49
- AYTU $3.45
- Technical
- Relative Strength Index (RSI)
- EDUC 45.16
- AYTU 41.21
- Support Level
- EDUC $1.19
- AYTU $0.99
- Resistance Level
- EDUC $1.34
- AYTU $1.10
- Average True Range (ATR)
- EDUC 0.11
- AYTU 0.08
- MACD
- EDUC 0.01
- AYTU 0.01
- Stochastic Oscillator
- EDUC 66.12
- AYTU 55.56
About EDUC Educational Development Corporation
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.